Nanomaterials (Apr 2024)

Efficient Production of Self-Assembled Bioconjugate Nanovaccines against <i>Klebsiella pneumoniae</i> O2 Serotype in Engineered <i>Escherichia coli</i>

  • Yan Zhang,
  • Peng Sun,
  • Ting Li,
  • Juntao Li,
  • Jingqin Ye,
  • Xiang Li,
  • Jun Wu,
  • Ying Lu,
  • Li Zhu,
  • Hengliang Wang,
  • Chao Pan

DOI
https://doi.org/10.3390/nano14080728
Journal volume & issue
Vol. 14, no. 8
p. 728

Abstract

Read online

Nanoparticles (NPs) have been surfacing as a pivotal platform for vaccine development. In our previous work, we developed a cholera toxin B subunit (CTB)-based self-assembled nanoparticle (CNP) and produced highly promising bioconjugate nanovaccines by loading bacterial polysaccharide (OPS) in vivo. In particular, the Klebsiella pneumoniae O2 serotype vaccine showcased a potent immune response and protection against infection. However, extremely low yields limited its further application. In this study, we prepared an efficient Klebsiella pneumoniae bioconjugate nanovaccine in Escherichia coli with a very high yield. By modifying the 33rd glycine (G) in the CNP to aspartate (D), we were able to observe a dramatically increased expression of glycoprotein. Subsequently, through a series of mutations, we determined that G33D was essential to increasing production. In addition, this increase only occurred in engineered E. coli but not in the natural host K. pneumoniae strain 355 (Kp355) expressing OPSKpO2. Next, T-cell epitopes were fused at the end of the CNP(G33D), and animal experiments showed that fusion of the M51 peptide induced high antibody titers, consistent with the levels of the original nanovaccine, CNP-OPSKpO2. Hence, we provide an effective approach for the high-yield production of K. pneumoniae bioconjugate nanovaccines and guidance for uncovering glycosylation mechanisms and refining glycosylation systems.

Keywords